谷氨酸钠对复发性前列腺癌男性PSMA放射性示踪剂摄取的影响:一项前瞻性、随机、双盲、安慰剂对照的个体内影像研究
这项前瞻性、双盲、安慰剂对照研究纳入10例生化复发前列腺癌患者,每人自身对照,间隔3-7天分别口服12.7克谷氨酸钠(MSG)或安慰剂后行18F-DCFPyL PET/CT。MSG后唾液腺、肾脏及其他正常器官的PSMA放射性示踪剂摄取显著降低,但恶性病灶摄取也相应显著降低。
要点
- MSG后腮腺、颌下腺和肾脏SULmax分别降低24%±14%、35%±11%和23%±26%,均有统计学意义。
- 泪腺、肝脏、脾脏和肠道摄取也显著降低,血池SULmean轻度降低11%±13%。
- 恶性病灶SULmax中位降低33%(范围-1%至75%),可能限制该方法的诊断和治疗应用。
核心结论
- 口服MSG显著降低了人受试者唾液腺、肾脏和其他正常器官的PSMA放射性示踪剂摄取,以18F-DCFPyL为例。
- 然而MSG导致肿瘤摄取相应降低,可能限制该方法在诊断和治疗应用中的益处。
研究设计与样本
- 前瞻性、双盲、安慰剂对照研究,纳入10例生化复发前列腺癌患者,每例受试者作为自身对照。
- 间隔3-7天口服12.7克MSG或安慰剂后行18F-DCFPyL PET/CT显像,对感兴趣区数据进行配对分析。
主要发现
- 共分析142个病理病灶及正常组织。
- MSG后腮腺SULmax降低24%±14%(P=0.001),颌下腺降低35%±11%(P<0.001),肾脏降低23%±26%(P=0.014)。
- MSG后泪腺降低49%±13%(P<0.001),肝脏降低15%±6%(P<0.001),脾脏降低28%±13%(P=0.001),肠道降低44%±13%(P<0.001)。
- MSG后血池SULmean轻度降低11%±13%(P=0.021)。
- 恶性病灶MSG后较安慰剂后SULmean、SULpeak和SULmax显著降低,SULmax中位降低33%(范围-1%至75%,P<0.001)。
关键数值与推荐
- 安慰剂或MSG给药后均无显著不良事件发生,生命体征稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- MSG导致肿瘤摄取相应降低,可能限制该方法在诊断和治疗应用中的益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prostate-specific membrane antigen (PSMA) is an excellent target for theranostic applications in prostate cancer. However, PSMA-targeted radioligand therapy can cause undesirable effects due to high accumulation of PSMA radiotracers in salivary glands and kidneys. This study assessed orally administered monosodium glutamate (MSG) as a potential means of reducing kidney and salivary gland radiation exposure using a PSMA-targeting radiotracer. Methods: This prospective, double-blind, placebo-controlled study enrolled 10 patients with biochemically recurrent prostate cancer. Each subject served as his own control. PET/CT imaging sessions using 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) were performed 3-7 d apart, after oral administration of either 12.7 g of MSG or placebo. Data from the 2 sets of images were analyzed by placing regions of interest on lacrimal, parotid, and submandibular glands; left ventricle; liver; spleen; kidneys; bowel; urinary bladder; gluteus muscle; and malignant lesions. The results from MSG and placebo scans were compared by paired analysis of the region-of-interest data. Results: In total, 142 pathologic lesions along with normal tissues were analyzed. As hypothesized a priori, there was a significant decrease in SUVmax corrected for lean body mass (SULmax) on images obtained after MSG administration in the parotids (24% ± 14%, P = 0.001), submandibular glands (35% ± 11%, P < 0.001), and kidneys (23% ± 26%, P = 0.014). Significant decreases were also observed in the lacrimal glands (49% ± 13%, P < 0.001), liver (15% ± 6%, P < 0.001), spleen (28% ± 13%, P = 0.001), and bowel (44% ± 13%, P < 0.001). A mildly lower blood pool SULmean was observed after MSG administration (decrease of 11% ± 13%, P = 0.021). However, significantly lower radiotracer uptake in terms of SULmean, SULpeak, and SULmax was observed in malignant lesions on scans performed after MSG administration than on the placebo studies (SULmax median decrease, 33%; range, -1% to 75%; P < 0.001). No significant adverse events occurred after placebo or MSG administration, and vital signs were stable. Conclusion: Orally administered MSG significantly decreased salivary gland, kidney, and other normal-organ PSMA radiotracer uptake in human subjects, using 18F-DCFPyL as an exemplar. However, MSG caused a corresponding reduction in tumor uptake, which may limit the benefits of this approach for diagnostic and therapeutic applications.
引用
- Harsini S, Saprunoff H, Alden T, et al. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study. J Nucl Med. 2020. PMID: 32385167. doi:10.2967/jnumed.120.246983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。